Rein Therapeutics, Inc. (RNTX)
0.6079
0.00 (0.00%)
USD |
NASDAQ |
Nov 06, 10:36
Rein Therapeutics Total Assets (Quarterly) : 65.97M for June 30, 2026
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 65.97M |
| March 31, 2026 | 26.29M |
| December 31, 2025 | 26.38M |
| September 30, 2025 | 53.71M |
| June 30, 2025 | 57.48M |
| March 31, 2025 | 57.63M |
| December 31, 2024 | 69.24M |
| September 30, 2024 | 104.22M |
| June 30, 2024 | 109.40M |
| March 31, 2024 | 99.19M |
| December 31, 2023 | 119.29M |
| September 30, 2023 | 12.82M |
| June 30, 2023 | 13.99M |
| March 31, 2023 | 17.16M |
| December 31, 2022 | 22.01M |
| September 30, 2022 | 27.23M |
| June 30, 2022 | 33.77M |
| March 31, 2022 | 40.26M |
| December 31, 2021 | 48.48M |
| September 30, 2021 | 54.77M |
| June 30, 2021 | 60.53M |
| March 31, 2021 | 64.67M |
| December 31, 2020 | 16.34M |
| September 30, 2020 | 22.24M |
| Date | Value |
|---|---|
| June 30, 2020 | 26.12M |
| March 31, 2020 | 20.37M |
| December 31, 2019 | 28.12M |
| September 30, 2019 | 33.95M |
| June 30, 2019 | 40.19M |
| March 31, 2019 | 22.40M |
| December 31, 2018 | 30.31M |
| September 30, 2018 | 38.13M |
| June 30, 2018 | 42.58M |
| March 31, 2018 | 45.83M |
| December 31, 2017 | 52.69M |
| September 30, 2017 | 59.04M |
| June 30, 2017 | 15.10M |
| March 31, 2017 | 17.16M |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | 5.94M |
| September 30, 2015 | 9.80M |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | 17.73M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.794B |
| Alnylam Pharmaceuticals, Inc. | 7.995B |
| Anika Therapeutics, Inc. | 183.47M |
| Savara, Inc. | 192.14M |
| Vericel Corp. | 502.87M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 10.77M |
| Shareholders Equity (Quarterly) | 55.20M |
| Current Ratio | 4.270 |